Major U.S. equities indexes eked out minor gains on Tuesday, even as the latest Consumer Confidence Index data showed economic expectations declined in March, reaching their lowest point in over a decade.

The S&P 500 inched 0.2% higher, notching its third consecutive winning session. The Nasdaq added 0.5%, while the Dow ended with a minimal gain of less than 0.1%.

The S&P 500’s top performance on Tuesday came from shares of International Paper (IP), which surged 6.5% after the packaging supplier provided an upbeat growth outlook at its annual investor day. The company highlighted ongoing efforts to streamline its production footprint, including the closure of seven plants as well as efficiency measures at other facilities. After a takeover effort last year by Brazilian paper firm Suzano failed to materialize, International Paper acquired fellow sustainable packaging producer DS Smith in January, indicating that the combination would help drive growth.

Copper futures prices advanced more than 2%, approaching record levels, with unease surrounding tariff policies and concerns about supply providing a boost to the industrial metal. Shares of Freeport-McMoRan (FCX), the world’s largest publicly traded copper producer, added 3.4%.

Shares of cybersecurity firm CrowdStrike Holdings (CRWD) jumped 3.3% after the research firm BTIG upgraded its view on the stock to “buy” from “neutral.” Analysts suggested that CrowdStrike has been successful in moving past last year’s global IT outage, noting that the company’s performance since the incident has improved forecasting visibility. BTIG also believes CrowdStrike has the potential to outperform consensus estimates for its annual recurring revenue (ARR) in fiscal 2027.

Shares of delivery giant United Parcel Service (UPS) slipped 5.1%, falling the furthest of any S&P 500 stock, after Bank of America trimmed its earnings forecast for the current quarter. Analysts noted that trade-related uncertainty and winter weather were weighing on demand, also reducing their outlook for the company’s quarterly domestic parcel volume.

Merck (MRK) shares dropped 4.8% following reports that the U.S. drugmaker has inked a licensing deal worth as much as $2 billion with China-based Jiangsu Hengrui Pharmaceuticals. The agreement gives Merck exclusive rights to the experimental oral heart disease treatment HRS-5346, a member of a class of drugs designed to prevent the formation of cholesterol.

Shares of fellow pharmaceutical firm AbbVie (ABBV) fell 3.7% after the company filed a lawsuit against Genmab, a Danish biotech firm and long-time AbbVie collaborator. AbbVie reportedly claims that Genmab and its recent acquisition, ProfoundBio, knowingly participated in the misappropriation of confidential company technology related to antibody-drug conjugates (ADCs).